Save
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism
Author(s): ,
M. V. Huisman
Affiliations:
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
Correspondence: Menno V. Huisman, Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands|Tel.: +31 71 529 8127|E‐mail: m.v.huisman@lumc.nl
,
M. Ferreira
Affiliations:
Department of Internal Medicine, Hospital Garcia de Orta, Almada, Portugal
,
M. Feuring
Affiliations:
Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany
,
M. Fraessdorf
Affiliations:
Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany
F. A. Klok
Affiliations:
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
ISTH Academy. Huisman M. Sep 4, 2018; 230970
Prof. Dr. Menno Huisman
Prof. Dr. Menno Huisman

Access to Premium content is currently a membership benefit.


Click here to join ISTH or renew your membership.

Journal Abstract
Discussion Forum (0)
Rate & Comment (0)


Introduction
Although direct oral anticoagulants (DOACs) are associated with a better safety profile than warfarin in patients with acute venous thromboembolism (VTE), direct factor Xa inhibitors involve a higher risk of abnormal uterine bleeding (AUB). We aimed to determine the risk of AUB during anticoagulation with dabigatran compared with warfarin.
Methods
Post‐hoc analysis of the pooled RE‐COVER studies and the RE‐MEDY trial. Incidences of AUB, based on a defined preferred terms search for adverse events, in female patients aged 18–50 years treated with dabigatran, were compared with those in women treated with warfarin.
Results
Of the 2964 women included in the above‐mentioned trials, 1280 women were in the relevant age category (18–50 years) and included in the current analysis. A total of 643 patients were randomized to treatment with dabigatran and 637 to treatment with warfarin. The overall rate of AUB was 8.1%, 5.9% for the women treated with dabigatran and 9.6% in those treated with warfarin, for an odds ratio for dabigatran‐treated patients of 0.59 (95% confidence interval [CI], 0.39–0.90; P = 0.015). In the dabigatran‐treated patients, three (0.5%) suffered major bleeding (MB) vs. five (0.8%) in the warfarin‐treated patients (HR, 0.65; 95% CI, 0.15–2.72). MB or non‐major relevant bleeding occurred in 30 (4.7%) patients randomized to receive dabigatran and 57 (8.9%) randomized to receive warfarin (HR, 0.53; 95% CI, 0.34–0.83). None of the bleeding events was fatal.
Conclusion
Dabigatran treatment was associated with a significantly (41%) lower risk of AUB than warfarin. Future studies in daily practice are needed to corroborate these findings.
Keyword(s)
abnormal uterine bleeding, anticoagulation, bleeding, dabigatran, direct oral anticoagulants
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings